Kosaka T, Mishima H K, Kiuchi Y, Kataoka K
Department of Ophthalmology, Hiroshima University School of Medicine, Japan.
Jpn J Ophthalmol. 1995;39(4):368-76.
The effects of prostaglandins (PGs) and PG-related compounds on the blood-ocular barriers were examined using pigmented rabbits. Latanoprost (PhXA41), PGF2(alpha)-isopropyl ester (PGF2(alpha)-IE) or PGE2 was topically applied once only or once daily for 8 weeks. Aqueous flare was measured with a laser flare-cell meter, and morphological changes in the ciliary processes after repeated applications of a test drug were investigated by means of light or electron microscopy using horseradish peroxidase (HRP) as a tracer. PGF2(alpha)-IE and PGE2, but not PhXA41, caused an initial rise in the aqueous flare after application. On the other hand, no morphological changes were found in the ciliary processes after 8-week PhXA41 application. After 8-week application of PGF2(alpha)-IE or PGE2 dilation of ciliary channels in the ciliary processes were found. Leakage of intravenously injected fluorescein was measured by a vitreous fluorophotometer after an intravitreal injection of PGE2, PGF2(alpha), or PhXA41. Vitreous fluorescence was significantly higher in treated eyes than in controls after intravitreal injection of PGE2 or PGF2(alpha), while it showed no significant change after intravitreal injection of PhXA41. Only PGE2 caused morphological changes in the retina. These results suggest that PhXA41 does not compromise the integrity of the blood-ocular barriers, and has a potential as a future anti-glaucoma eyedrop.
利用有色家兔研究了前列腺素（PGs）及PG相关化合物对血眼屏障的影响。将拉坦前列素（PhXA41）、前列腺素F2α异丙酯（PGF2α-IE）或前列腺素E2仅单次局部应用或每日一次应用8周。用激光散射细胞仪测量房水闪光，并以辣根过氧化物酶（HRP）作为示踪剂，通过光学显微镜或电子显微镜研究重复应用受试药物后睫状体的形态变化。PGF2α-IE和前列腺素E2（而非PhXA41）在应用后可引起房水闪光的初始升高。另一方面，应用PhXA41 8周后，在睫状体未发现形态学变化。应用PGF2α-IE或前列腺素E2 8周后，发现睫状体中的睫状管扩张。玻璃体内注射前列腺素E2、前列腺素F2α或PhXA41后，用玻璃体荧光光度计测量静脉注射荧光素的渗漏情况。玻璃体内注射前列腺素E2或前列腺素F2α后，治疗组眼的玻璃体荧光明显高于对照组，而玻璃体内注射PhXA41后未显示出明显变化。仅前列腺素E2引起视网膜形态学变化。这些结果表明，PhXA41不会损害血眼屏障的完整性，具有作为未来抗青光眼滴眼液的潜力。
